Personalized Medicine Coalition elects Dr. Toni Andreu as member of the Board of Directors

Published 27 May 2019

We are excited to announce that Dr. Toni Andreu, our Scientific Director, is elected as member of the Board of Directors of the Personalized Medicine Coalition (PMC).

Press release as published on the PMC website:

“Coalition Enhances Capacity to Advance Personalized Medicine in US & Around the World With Addition of Board Members Representing Researchers, Patients, Industry

Washington (May 16, 2019)

In a development that enhances the Personalized Medicine Coalition (PMC)’s capacity to promote the understanding and adoption of the technologies and treatments underpinning personalized medicine for the benefit of patients and health systems in the U.S. and around the world, the Coalition is pleased to announce that it has added Dr. Antonio L. Andreu, Scientific Director of the European Infrastructure for Translational Medicine (EATRIS), Dr. Lori Frank, a Senior Behavioral Scientist with the RAND Corporation who sits on the Medical, Scientific and Memory Screening Advisory Board of the Alzheimer’s Foundation of America (AFA), and Mr. Mark P. Stevenson, Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific, to its multi-stakeholder board of directors.

Dr. Andreu, who began his career as a researcher specializing in the genetics and genomics of rare diseases, went on to create Spain’s national personalized medicine program during his tenure as Director of the Spanish national institute of health, called the Instituto de Salud Carlos III.

Dr. Frank brings a deep background in the patient advocacy community. As a member of AFA’s Medical, Scientific and Medical Screening Advisory Board, Dr. Frank offers expert insight on scientific issues surrounding Alzheimer’s disease and related dementias.

Mr. Stevenson, Executive Vice President and Chief Operating Officer at Thermo Fisher, helps lead the company’s global efforts to advance personalized medicine by supporting commercialization, evidence development and advocacy to help enable delivery of molecular diagnostics and targeted therapeutics from translational research into the clinic.”

You can read the original press release here.